A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

Overview of attention for article published in Journal of Neurology, August 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

blogs: 2 blogs

patent: 4 patents

Readers on

mendeley: 69 Mendeley

Summary Blogs Patents

So far, Altmetric has seen 4 patents that reference this research output.

Depot systems comprising glatiramer or pharmacologically acceptable salt thereof

Grant US-RE49251-E1

United States of America

Methods for suppressing or alleviating primary or secondary progressive multiple…

Grant US-11167003-B2

United States of America

Process for manufacturing glatiramer acetate product

Grant US-9763993-B2

United States of America

Low frequency glatiramer acetate therapy

Grant US-9402874-B2

United States of America

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.